Literature DB >> 20439046

Diarrhea, clostridium difficile, and intestinal inflammation in residents of a long-term care facility.

Laurie Archbald-Pannone1, Jesus Emmanuel Sevilleja, Richard Guerrant.   

Abstract

INTRODUCTION: Long-term care facilities (LTCF) residents have been estimated to have the highest incidence of diarrheal illness among adults living in the developed world. This study describes undiagnosed diarrhea, intestinal inflammation, and Clostridium difficile colonization in a LTC population and explores whether these are associated with functional decline, as defined by weight loss or a change in cognitive or ADL status.
METHODS: An observational study of a convenience sampling of residents in a 180-bed LTCF was obtained; evaluation of stool and medical records was done. Stool specimens were evaluated for consistency, gross blood, inflammation (via quantitative fecal lactoferrin, IBD-SCAN), and C difficile (via PCR for gdh). SPSS and STATA were used and significance was set at P < .05.
RESULTS: There were 46 stools collected; 13 of the subjects were male, 28 were older than 65 years, and 35 were prescribed 5 to 15 medications. Twenty-six of the 46 stools collected had elevated quantitative fecal lactoferrin levels. Although only 5 subjects were reported to have diarrhea (4 with elevated lactoferrin), 28 stool specimens were observed to be liquid or semi-solid (19 with elevated lactoferrin), and these liquid/ semisolid stools were significantly correlated with lactoferrin positivity (P = .017). In analysis of functional status, there was no statistically significant association between change in ADL (n = 17) or cognitive status (n = 5) and elevated lactoferrin. However, all 3 subjects who had significant weight loss had elevated lactoferrin, although the mean fecal lactoferrin was not statistically different from those without weight loss. Of the 2 samples with C difficile, both were liquid and, when compared with all other liquid stools (n = 22), the mean lactoferrin was statistically higher (134.1 versus 28.8 microg/mL, P = .008). These 2 subjects had neither weight loss nor change in cognitive status, but 1 had a change in ADL status. DISCUSSION AND
CONCLUSIONS: Diarrhea in LTCF residents is underdiagnosed. Diarrhea and the presence of C difficile in the stool are associated with intestinal inflammation, as detected by fecal lactoferrin. With our small numbers, we were not able to identify a specific link; however, we were able to identify a correlation between weight loss and intestinal inflammation, but, with just 2 samples, not C difficile colonization. This relationship highlights the importance of larger studies to further examine the rate of diarrhea in LTCF; the effect of diarrhea and intestinal inflammation on weight loss; and the interaction of C difficile colonization with weight loss, malnutrition, and functional decline. Copyright (c) 2010 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439046      PMCID: PMC2864938          DOI: 10.1016/j.jamda.2009.09.006

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  22 in total

1.  Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary.

Authors:  Gabriella Terhes; Edit Urbán; József Sóki; Kanjo Abdul Hamid; Elisabeth Nagy
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

2.  Clostridium difficile-associated disease in long-term care facilities.

Authors:  D W Bentley
Journal:  Infect Control Hosp Epidemiol       Date:  1990-08       Impact factor: 3.254

Review 3.  Clostridium difficile in the long-term care setting.

Authors:  Alex T Makris; Steven Gelone
Journal:  J Am Med Dir Assoc       Date:  2007-06       Impact factor: 4.669

4.  Lack of care giver hand contamination with endemic bacterial pathogens in a nursing home.

Authors:  E Larson; L Bobo; R Bennett; S Murphy; S T Seng; J T Choo; J Sisler
Journal:  Am J Infect Control       Date:  1992-02       Impact factor: 2.918

5.  Diarrheal deaths in the United States, 1979 through 1987. A special problem for the elderly.

Authors:  J F Lew; R I Glass; R E Gangarosa; I P Cohen; C Bern; C L Moe
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Hospitalizations involving gastroenteritis in the United States, 1985: the special burden of the disease among the elderly.

Authors:  R E Gangarosa; R I Glass; J F Lew; J R Boring
Journal:  Am J Epidemiol       Date:  1992-02-01       Impact factor: 4.897

7.  Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors.

Authors:  K J Walker; S S Gilliland; K Vance-Bryan; J A Moody; A J Larsson; J C Rotschafer; D R Guay
Journal:  J Am Geriatr Soc       Date:  1993-09       Impact factor: 5.562

Review 8.  Approach to acute diarrhea in the elderly.

Authors:  R G Bennett; W B Greenough
Journal:  Gastroenterol Clin North Am       Date:  1993-09       Impact factor: 3.806

9.  Clostridium difficile in acute and long-stay elderly patients.

Authors:  R R Campbell; D Beere; G K Wilcock; E M Brown
Journal:  Age Ageing       Date:  1988-09       Impact factor: 10.668

10.  Clostridium difficile infection in a geriatric ward.

Authors:  I Monsieur; T Mets; S Lauwers; V De Bock; M Delmée
Journal:  Arch Gerontol Geriatr       Date:  1991 Nov-Dec       Impact factor: 3.250

View more
  11 in total

1.  Anorexia of aging: a true geriatric syndrome.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2012-05       Impact factor: 4.075

Review 2.  The Burden of Enteropathy and "Subclinical" Infections.

Authors:  Elizabeth T Rogawski; Richard L Guerrant
Journal:  Pediatr Clin North Am       Date:  2017-08       Impact factor: 3.278

3.  Delirium and other clinical factors with Clostridium difficile infection that predict mortality in hospitalized patients.

Authors:  Laurie R Archbald-Pannone; Timothy L McMurry; Richard L Guerrant; Cirle A Warren
Journal:  Am J Infect Control       Date:  2015-04-24       Impact factor: 2.918

Review 4.  Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.

Authors:  Shinsmon Jose; Rajat Madan
Journal:  Anaerobe       Date:  2016-04-05       Impact factor: 3.331

5.  MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammation.

Authors:  Linda D Bobo; Rana E El Feghaly; Yee-Shiuan Chen; Erik R Dubberke; Zhuolin Han; Alexandra H Baker; Jinmei Li; Carey-Ann D Burnham; David B Haslam
Journal:  Infect Immun       Date:  2012-12-21       Impact factor: 3.441

6.  Peripheral Inflammation and Functional Decline in the National Health and Nutrition Examination Survey Elderly Population.

Authors:  Aaron F Pannone; Xin-Qun Wang; Laurie R Archbald-Pannone
Journal:  J Am Geriatr Soc       Date:  2016-03       Impact factor: 5.562

7.  Clostridium difficile ribotype 027 is most prevalent among inpatients admitted from long-term care facilities.

Authors:  L R Archbald-Pannone; J H Boone; R J Carman; D M Lyerly; R L Guerrant
Journal:  J Hosp Infect       Date:  2014-07-30       Impact factor: 3.926

8.  Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection.

Authors:  J H Boone; J R DiPersio; M J Tan; S-J Salstrom; K N Wickham; R J Carman; H R Totty; R E Albert; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-18       Impact factor: 3.267

9.  Survey of C. difficile-Specific Infection Control Policies in Local Long-Term Care Facilities.

Authors:  Laurie Archbald-Pannone
Journal:  Int J Clin Med       Date:  2014-04-01

10.  Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.

Authors:  Andrew Swale; Fabio Miyajima; Paul Roberts; Amanda Hall; Margaret Little; Mike B J Beadsworth; Nick J Beeching; Ruwanthi Kolamunnage-Dona; Chris M Parry; Munir Pirmohamed
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.